• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Consumer Cyclical·6242.TWO
Share

Li Kang Biomedical Co., Ltd. Stocks

NT$ 33.9Last Updated 21.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 33.35M

NT$ 33.9
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Li Kang Biomedical Co., Ltd. specializes in the development and distribution of nutritional supplements, cosmeceuticals, and health-focused beverages. Beyond its product lines, the company also provides consulting and operational support for tourism factories, and offers telemarketing solutions. Established in 1982, the firm initially operated under the name BAFO Technologies Corporation, before adopting its current moniker, Li Kang Biomedical Co., Ltd., in September 2014. The company maintains its headquarters in Tainan City, Taiwan.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 6242.TWO is 162 and suggests 379% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 11:15

Tesla has scaled back its capital expenditure plans for 2026. Why investors weren't pleased

22.10.2026 10:48

Top Stories This Morning: Meta Has Increased Its AI Spending; Anthropic Has Unveiled a Competitor to Muse

22.10.2026 10:33

Millions of Hacking Attempts: 5 Questions About a Critical Network Vulnerability Discovered by AI

21.10.2026 22:53

"Ambitions Greater Than Anyone Else's": JPMorgan Expects SpaceX Shares to Triple in Value

21.10.2026 22:20

Berkshire Hathaway shares hit a new record high—for the first time since Buffett announced his retirement

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026